1
|
Baerwald C, Stemmler E, Gnüchtel S, Jeromin K, Fritz B, Bernateck M, Adolf D, Taylor PC, Baron R. Predictors for severe persisting pain in rheumatoid arthritis are associated with pain origin and appraisal of pain. Ann Rheum Dis 2024:ard-2023-225414. [PMID: 38816064 DOI: 10.1136/ard-2023-225414] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2023] [Accepted: 05/04/2024] [Indexed: 06/01/2024]
Abstract
OBJECTIVES To determine the proportion of patients with rheumatoid arthritis (RA) with severe persisting pain and to identify predictive factors despite treatment-controlled disease activity. METHODS This prospective multicentre study included outpatients with RA scheduled for escalation of anti-inflammatory treatment due to active disease and severe pain (Disease Activity Score 28 (DAS28)>3.2 and Visual Analogue Scale (VAS)>50). At week 24, patients were stratified into reference group (DAS28 improvement>1.2 or DAS28≤3.2 and VAS pain score<50), non-responders (DAS28 improvement≤1.2 and DAS28>3.2, regardless of VAS pain score) and persisting pain group (DAS28 improvement>1.2 or DAS28≤3.2 and VAS pain score≥50). The former two subgroups ended the study at week 24. The latter continued until week 48. Demographic data, DAS28-C reactive protein, VAS for pain, painDETECT Questionnaire (PD-Q) to identify neuropathic pain (NeP) and the Pain Catastrophising Scale were assessed and tested for relation to persisting pain. RESULTS Of 567 patients, 337 (59.4%) were classified as reference group, 102 (18.0%) as non-responders and 128 (22.6%) as patients with persisting pain. 21 (8.8%) responders, 28 (35.0%) non-responders and 27 (26.5%) persisting pain patients tested positive for NeP at week 24. Pain catastrophising (p=0.002) and number of tender joints (p=0.004) were positively associated with persisting pain at week 24. Baseline PD-Q was not related to subsequent persisting pain. CONCLUSIONS Persisting and non-nociceptive pain occur frequently in RA. Besides the potential involvement of NeP, pain catastrophising and a higher number of tender joints coincide with persisting pain.
Collapse
Affiliation(s)
- Christoph Baerwald
- Zentrum für Seltene Erkrankungen, University Hospital Leipzig, Leipzig, Germany
| | | | | | | | - Björn Fritz
- AbbVie Deutschland GmbH & Co KG, Wiesbaden, Germany
| | | | | | - Peter C Taylor
- Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Botnar Research Centre, Oxford, UK
| | - Ralf Baron
- Department of Neurology, University Hospital Schleswig Holstein, Kiel, Germany
| |
Collapse
|
2
|
Wang J, Vordenbäumen S, Schneider M, Brinks R. Population-based epidemiological projections of rheumatoid arthritis in Germany until 2040. Scand J Rheumatol 2024; 53:161-172. [PMID: 38358097 DOI: 10.1080/03009742.2024.2312693] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2023] [Accepted: 01/29/2024] [Indexed: 02/16/2024]
Abstract
OBJECTIVES Our aim was to conduct a population-based projection to estimate the number of rheumatoid arthritis (RA) cases in Germany until 2040. METHOD Data obtained from a report published in 2017 (doi:10.20364/VA-17.08) were used for future prediction analysis. The data were originally collected by the German Central Institute for Statutory Health Insurance. We used the illness-death model to estimate future numbers of RA cases, considering nine possible scenarios based on different incidence and mortality rates. RESULTS In the baseline scenario, the number of women with RA is projected to increase by 417 000 cases and men by 179 000 cases by 2040, compared with 2015. Peak numbers of cases are concentrated in the 70-80-year-old age group, particularly among women. In the most favourable scenario (scenario 2), assuming a decreasing incidence, the total number of RA cases is projected to rise by 284 000 by 2040, reflecting a 38% relative increase from 2015 to 2040. The least favourable scenario (scenario 9), assuming an increasing incidence, projects a significant burden on the healthcare system. The total number of RA cases is expected to rise by 1.16 million by 2040, marking a substantial 158% relative increase from 2015 to 2040. CONCLUSIONS Our research emphasizes a discernible trend: with an ageing society, improving treatment effectiveness, and declining all-cause mortality, we anticipate a rise in the absolute numbers of RA cases in Germany in the coming years. Our models robustly support this viewpoint, underscoring impending challenges for healthcare systems. Addressing these challenges demands multifaceted interventions.
Collapse
Affiliation(s)
- J Wang
- Institute of Biometry and Epidemiology, The German Diabetes Center, Heinrich Heine University Düsseldorf, Düsseldorf, Germany
| | - S Vordenbäumen
- Department of Rheumatology, St. Elisabeth-Hospital Meerbusch-Lank, Meerbusch, Germany
- Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany
| | - M Schneider
- Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany
| | - R Brinks
- Chair for Medical Biometry and Epidemiology, University of Witten/Herdecke, Witten, Germany
| |
Collapse
|
3
|
Baquet-Walscheid K, Neß T, Maier PC, Lapp T. Peripheral Ulcerative Keratitis: Clinical Characteristics, Differential Diagnoses and Therapeutic Concepts. Klin Monbl Augenheilkd 2024; 241:633-643. [PMID: 38776930 DOI: 10.1055/a-2290-4420] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/25/2024]
Abstract
Peripheral ulcerative keratitis (PUK) is an inflammatory disease of the peripheral cornea, which may frequently be associated with several rare, but potentially life-threatening systemic diseases. The inflammatory pathogenesis of PUK results from humoral and cell-mediated inflammation. The diagnosis is usually based on the typical clinical findings and always requires detailed diagnostic testing to identify a potential systemic underlying disease. Treatment includes topical and systemic immunosuppressive and immunomodulatory therapeutic strategies and, in the event of impending or existing perforation, also various surgical interventions. PUK is a potentially blinding disease that initially affects the periphery, but, if left untreated, can lead to destruction of the entire cornea. Interdisciplinary diagnostic testing and therapy are crucial to preserve vision in the affected patients and reduce morbidity and mortality. The following article provides an overview of the pathophysiology, clinical findings, possible underlying systemic diseases, relevant differential diagnoses and therapeutic strategies.
Collapse
Affiliation(s)
- Karoline Baquet-Walscheid
- Augenzentrum am St. Franziskus-Hospital Münster, Deutschland
- Medizinische Fakultät, Universität Duisburg-Essen, Essen, Deutschland
| | - Thomas Neß
- Klinik für Augenheilkunde, Universitätsklinikum Freiburg, Deutschland
| | | | - Thabo Lapp
- Augenzentrum am St. Franziskus-Hospital Münster, Deutschland
- Klinik für Augenheilkunde, Universitätsklinikum Freiburg, Deutschland
| |
Collapse
|
4
|
Schultz O, Fiehn C, Kneitz C, Picker N, Kromer D, Zignani M, De Leonardis F, Orzechowski HD, Gurrath M, Krüger K. Real-world experience with filgotinib for rheumatoid arthritis in Germany : A retrospective chart review. Z Rheumatol 2024:10.1007/s00393-024-01506-x. [PMID: 38689038 DOI: 10.1007/s00393-024-01506-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/21/2024] [Indexed: 05/02/2024]
Abstract
BACKGROUND Real-world data for filgotinib, a Janus kinase (JAK)1 inhibitor, are limited in patients with rheumatoid arthritis (RA). OBJECTIVES To explore real-world filgotinib use in patients with RA in Germany. MATERIALS AND METHODS This retrospective chart review included patients aged ≥ 18 years with confirmed moderate to severe RA who initiated filgotinib before December 1, 2021, with ≥ 6 months of medical records available prior to filgotinib initiation or after initial diagnosis. Patient characteristics, prior treatments, reasons for initiating/discontinuing filgotinib, disease activity, dose adjustments and concomitant treatments were recorded. RESULTS In total, 301 patients from 20 German rheumatology outpatient units were included. One-third were aged ≥ 65 years and almost half had ≥ 1 cardiovascular (CV) risk factor. Most patients initiated filgotinib as monotherapy (83.7%; 12.7% of whom with glucocorticoids) and at the 200 mg dose (84.7%); higher proportions of those initiating the 100 versus 200 mg dose were aged ≥ 65 years and had renal impairment or ≥ 1 CV risk factor. Oral administration (78.4%), fast onset of action (66.8%) and administration as monotherapy (65.4%) were the most common reasons for initiating filgotinib. At 12 months, 41 (18.4%) patients had discontinued filgotinib, most commonly due to lack of effectiveness. After 6‑months of follow-up, 36.8% of patients had achieved Clinical Disease Activity Index (CDAI) remission and 45.6% had achieved CDAI low disease activity. CONCLUSIONS In clinical practice in Germany, reasons for initiating filgotinib in patients with RA were related to dosing flexibility and general JAK inhibitor attributes. Filgotinib was used predominantly as monotherapy and was effective and generally well tolerated; however, longer-term data in larger, prospective cohorts are needed.
Collapse
Affiliation(s)
- Olaf Schultz
- ACURA Kliniken Baden-Baden/Rheumazentrum, Rotenbachtalstraße 5, 76530, Baden-Baden, Germany.
| | - Christoph Fiehn
- Praxis for Rheumatology and Clinical Immunology, Medical Center Baden-Baden, Baden-Baden, Germany
| | | | - Nils Picker
- Ingress-Health HWM GmbH-A Cytel Company, Wismar, Germany
| | - Daniel Kromer
- Ingress-Health HWM GmbH-A Cytel Company, Berlin, Germany
| | | | | | | | | | - Klaus Krüger
- Rheumatologisches Praxiszentrum St. Bonifatius, Munich, Germany
| |
Collapse
|
5
|
Birkner B, Rech J, Edelmann E, Verheyen F, Schett G, Stargardt T. Treatment patterns of individualized real-life tapering approaches based on shared decision-making in rheumatoid arthritis. Z Rheumatol 2024; 83:142-150. [PMID: 37351593 PMCID: PMC10901995 DOI: 10.1007/s00393-023-01380-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/15/2023] [Indexed: 06/24/2023]
Abstract
OBJECTIVE To provide real-world evidence on patient-individual tapering patterns of disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients in daily clinical practice. METHODS Data obtained through a controlled prospective cohort study in Germany conducted from July 2018 to March 2021 were analyzed. Participants consist of RA patients in sustained remission who were eligible for DMARD tapering at enrolment. Data from RA patients who experienced tapering of DMARDs at least once during the observational period (n = 200) were used. Descriptive analyses of medical outcomes at baseline and at time of first tapering, time to first tapering, tapering patterns by substance group, and tapering intensity were documented. RESULTS We did not observe meaningful differences in either disease activity or quality of life measures between substance groups at enrolment, time of first tapering, and at 6 or 12 months after tapering. Median time until first tapering varied between substance groups (csDMARDs: 108 days; bDMARDs: 189 days; combination: 119 days). Most patients received one iteration of tapering only (147/200 patients, 73.5%). Dose reduction was applied for patients treated with csDMARDs (79/86 patients, 91.8%), spacing of interval was the most frequent strategy for patients treated with bDMARDs only (43/48 patients, 89.5%). Necessity for increased DMARD dosage was observed in only 10% of patients (20/200). Tapering intensity by substance was overall heterogenous, indicating high individualization. CONCLUSION We identify highly heterogeneous tapering patterns between substance groups and within substances. Identification and recognition of patient-individual approaches of tapering will help to further improve the management of RA for both patients and rheumatologists.
Collapse
Affiliation(s)
- Benjamin Birkner
- Hamburg Center for Health Economics (HCHE), Universität Hamburg, Esplanade 36, 20354, Hamburg, Germany.
| | - Jürgen Rech
- Medizinische Klinik 3 - Rheumatologie und Immunologie, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Ulmenweg 18, 91054, Erlangen, Germany.
- Deutsches Zentrum Immuntherapie, Friedrich-Alexander-Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany.
| | - Edmund Edelmann
- Berufsverband Deutscher Rheumatologen e.V, Hauptstraße 9, 13055, Berlin, Germany
| | - Frank Verheyen
- Techniker Krankenkasse, Bramfelder Straße 140, 22305, Hamburg, Germany
| | - Georg Schett
- Medizinische Klinik 3 - Rheumatologie und Immunologie, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Ulmenweg 18, 91054, Erlangen, Germany
- Deutsches Zentrum Immuntherapie, Friedrich-Alexander-Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, 91054, Erlangen, Germany
| | - Tom Stargardt
- Hamburg Center for Health Economics (HCHE), Universität Hamburg, Esplanade 36, 20354, Hamburg, Germany
| |
Collapse
|
6
|
Schäfer A, Kovacs MS, Eder A, Nigg A, Feuchtenberger M. Longitudinal assessment of liver stiffness using ARFI technique does not support increased risk of fibrosis in rheumatoid arthritis patients on methotrexate. J Ultrasound 2024:10.1007/s40477-023-00843-y. [PMID: 38227146 DOI: 10.1007/s40477-023-00843-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2023] [Accepted: 10/30/2023] [Indexed: 01/17/2024] Open
Abstract
AIMS To assess the liver stiffness in patients with rheumatoid arthritis treated with methotrexate monotherapy using non-invasive, ultrasound-based elastography (acoustic radiation force impulse (ARFI) imaging) in a longitudinal approach. METHODS In total, 23 MTX-naive patients were longitudinally assessed using acoustic radiation force impulse (ARFI) imaging. Baseline assessments were carried out between July 2018 and April 2019, and the follow-up evaluations took place after an average of 2.6 years. The main outcome variable was the mean shear wave velocity as measured by the ARFI method. It was calculated from 10 valid ARFI measurements for each patient. Inferential statistical analyses (within-group comparisons) were performed using t-tests for dependent samples or suitable nonparametric procedures. RESULTS The main finding was that observed ARFI shear wave velocities did not increase during the observation period. In fact, this parameter decreased over time from 1.07 m/s (SD = 0.23) at baseline without MTX exposure to 0.97 m/s (SD = 0.16) at follow-up after a mean of 2.6 years (P = 0.013). Moreover, the magnitude of the change in shear wave velocity could not be predicted by indicators of inflammation or disease activity, BMI, age, sex or NSAR intake (corresponding regression analysis: corrected R2 = 0.344; P = 0.296). CONCLUSIONS No increased risk of liver fibrosis was found in RA patients treated with MTX monotherapy during observation period.
Collapse
Affiliation(s)
- Arne Schäfer
- Diabetes Zentrum Mergentheim, Bad Mergentheim, Germany
- Medizinische Klinik und Poliklinik II, University Hospital Würzburg, Würzburg, Germany
| | | | - Anna Eder
- MVZ MED|BAYERN OST, Krankenhausstraße 1, 84489, Burghausen, Germany
| | - Axel Nigg
- MVZ MED|BAYERN OST, Krankenhausstraße 1, 84489, Burghausen, Germany
| | - Martin Feuchtenberger
- Medizinische Klinik und Poliklinik II, University Hospital Würzburg, Würzburg, Germany.
- MVZ MED|BAYERN OST, Krankenhausstraße 1, 84489, Burghausen, Germany.
| |
Collapse
|
7
|
Fiehn C, Zinke S, Haas JS, Meise D, Theil J, Gurrath M, Orzechowski HD. Real-world treatment persistence in patients with rheumatoid arthritis initiating DMARDs in Germany-a health insurance claims data analysis. Z Rheumatol 2023; 82:739-753. [PMID: 36757417 PMCID: PMC10627963 DOI: 10.1007/s00393-023-01323-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/28/2022] [Indexed: 02/10/2023]
Abstract
OBJECTIVE To investigate treatment patterns in patients with rheumatoid arthritis (RA) in Germany who had previously received conventional synthetic (cs) or biologic (b) disease-modifying antirheumatic drugs (DMARDs). METHODS Patients with RA who initiated treatment with a csDMARD, bDMARD, or Janus kinase (JAK) inhibitor between 2017 and 2018 and who had previously received csDMARD or bDMARD therapy were retrospectively selected from the Institute for Applied Health Research Berlin GmbH (InGef). Time on treatment and discontinuation risk were assessed using the Kaplan-Meier method. Cox regression identified variables associated with an increased discontinuation risk. RESULTS A total of 990 patients had received prior csDMARD therapy; 375 had received prior bDMARD therapy. Tumor necrosis factor (TNF)-α inhibitors and JAK inhibitors were the most commonly prescribed DMARD class in those previously treated with a csDMARD or bDMARD, respectively. In both cohorts, more patients received DMARD monotherapy than combination therapy. In the prior csDMARD cohort, median time on treatment was 276, 252, and 148 days with JAK inhibitors, TNF‑α inhibitors, and csDMARDs, respectively, and those treated with JAK or TNF‑α inhibitors were less likely to discontinue treatment than those on csDMARDs (log-rank test p-value < 0.01 for both comparisons); no significant differences were found within the prior bDMARD cohort. CONCLUSION This is among the first detailed analyses of RA treatment patterns in a real-world setting in Germany since the introduction of JAK inhibitors. TNF‑α inhibitors were the most commonly prescribed DMARD after failure of an initial csDMARD, while JAK inhibitors were the most common among patients previously treated with a bDMARD. In both groups, monotherapy with bDMARD or targeted synthetic DMARD was common. In the prior csDMARD cohort, treatment duration was significantly longer with JAK or TNF‑α inhibitors than with csDMARDs.
Collapse
Affiliation(s)
- Christoph Fiehn
- Rheumatology and Clinical Immunology Baden-Baden, Beethovenstr. 2, 76530, Baden-Baden, Germany.
| | | | | | | | | | | | | |
Collapse
|
8
|
Kaudewitz D, Lorenz HM. [Drug therapy of rheumatoid arthritis: where do biologics and novel synthetic disease-modifying antirheumatic drugs stand today?]. INNERE MEDIZIN (HEIDELBERG, GERMANY) 2023; 64:1005-1012. [PMID: 37493758 DOI: 10.1007/s00108-023-01554-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 06/13/2023] [Indexed: 07/27/2023]
Abstract
Biologics and Janus kinase (JAK) inhibitors play an important role in the treatment of rheumatoid arthritis. As new therapeutic developments have emerged in recent decades, the morbidity and mortality of rheumatoid arthritis have been significantly reduced. The characterization of the structure and function of immune cell receptors has led to the development of biologics that specifically inhibit cytokines and immune cell receptors. An important therapeutic addition was the approval of JAK inhibitors, which act directly on intracellular signaling by tyrosine kinases. This article provides an overview of the current therapeutic options for rheumatoid arthritis with a special focus on indication, mechanism of action and the place in the treatment algorithm of biologics and JAK inhibitors.
Collapse
Affiliation(s)
- Dorothee Kaudewitz
- Medizinische Klinik V, Klinik für Hämatologie, Onkologie und Rheumatologie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Deutschland.
| | - Hanns-Martin Lorenz
- Medizinische Klinik V, Klinik für Hämatologie, Onkologie und Rheumatologie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Deutschland
| |
Collapse
|
9
|
Schindler F, Schinkoethe T, Mahner S, Kolben T, Wuerstlein R, Culmsee C, Harbeck N, Eggersmann TK. Clinical relevance of potential self-medication drug interactions in antineoplastic and immune-modulating therapy among online pharmacy customers. Ther Adv Drug Saf 2023; 14:20420986231188845. [PMID: 37636837 PMCID: PMC10460262 DOI: 10.1177/20420986231188845] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2023] [Accepted: 06/19/2023] [Indexed: 08/29/2023] Open
Abstract
Background Modern oral antineoplastic and immune-modulating drugs offer an array of therapeutic advantages, and yet pose challenges in daily use for patients, physicians and pharmacists. In contrast to intravenous administration, these drugs are not subject to direct medical control. Recently, we have seen a huge rise in sales of non-prescription over-the-counter (OTC) medicines via the internet without any advice from a healthcare professional. Objectives The aim of this study was to investigate whether the risk of known potential drug-drug interactions between modern oral antineoplastic and immune-modulating drugs and OTC drugs differs between sales in traditional community pharmacies versus online pharmacies. Design Real-life sales data from community and online pharmacies were used as basis for the analysis. Methods We determined the most frequently purchased antineoplastic and immune-modulating drug-substances in 14 local community pharmacies within the Munich area, Germany and identified the OTC substance groups that could potentially cause interactions with oncological therapies. Using sales data from 11 local community pharmacies and three online pharmacies, we investigated whether OTC purchases differed between the two sales channels. Results We identified 10 relevant OTC substance classes and detected significant variations in patients' preferred sales channels between the drug classes. Certain OTC drugs, which seem to be bought more often over the internet, pose risks during antineoplastic and immune-modulating therapy. Conclusion Patients should therefore be proactively made aware of the corresponding risks in order not to jeopardize the activity of the antineoplastic and immune-modulating drugs and thus the success of their therapy.
Collapse
Affiliation(s)
- Florian Schindler
- Breast Center, Department of Obstetrics and Gynecology, LMU University Hospital, Munich, Germany
| | - Timo Schinkoethe
- Breast Center, Department of Obstetrics and Gynecology, LMU University Hospital, Munich, Germany
- CANKADO, Kirchheim, Germany
| | - Sven Mahner
- Breast Center, Department of Obstetrics and Gynecology, LMU University Hospital, Munich, Germany
| | - Thomas Kolben
- Breast Center, Department of Obstetrics and Gynecology, LMU University Hospital, Munich, Germany
| | - Rachel Wuerstlein
- Breast Center, Department of Obstetrics and Gynecology, LMU University Hospital, Munich, Germany
| | - Carsten Culmsee
- Institute for Pharmacology and Clinical Pharmacy, Biochemical-Pharmacological Center Marburg, Faculty of Pharmacy, University of Marburg, Marburg, Germany
| | - Nadia Harbeck
- Breast Center, Department of Obstetrics and Gynecology, LMU University Hospital, Marchioninistrasse 15, Munich 80333, Germany
| | - Tanja K. Eggersmann
- Breast Center, Department of Obstetrics and Gynecology, LMU University Hospital, Munich, Germany
- Department of Gynecological Endocrinology and Reproductive Medicine, University Hospital of Schleswig-Holstein, Luebeck, Germany
| |
Collapse
|
10
|
Bruck H, von Kiel C. [Autoimmune diagnostics in nephrology and rheumatology]. Dtsch Med Wochenschr 2023; 148:230-240. [PMID: 36848886 DOI: 10.1055/a-1844-9568] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/01/2023]
Abstract
Autoimmune diagnostics plays a central role in the detection of various acute and/or chronic diseases in both nephrology and rheumatology, which are associated with high morbidity and mortality if left untreated or not detected in time. Patients are threatened with significant limitations in everyday skills and quality of life due to loss of kidney function and dialysis, immobilizing and destructive joint processes or also significant damage of organ systems. In all of these autoimmune diseases, early diagnosis and treatment is of central importance for the further course and prognosis of disease.Antibodies play an essential role in the pathogenesis of autoimmune diseases. Antibodies are either directed against organ or tissue-specific antigens, such as in primary membranous glomerulonephritis or Goodpasture's syndrome, or they lead to a systemic disease such as systemic lupus erythematosus (SLE) or rheumatoid arthritis.Knowledge of the sensitivity and specificity of antibodies is crucial for the interpretation of antibody diagnostics results. Antibody detection can precede the clinical onset of the disease, and antibody titers often reflect disease activity. However, there are also false positive results. Detection of antibodies in the absence of disease symptoms often leads to uncertainty and unnecessary further diagnostics. Therefore, an unfounded "antibody screening" is not recommended.A rational antibody diagnostics is an integral part of the diagnostics and during treatment of nephrological and rheumatological diseases like glomerulonephrititis, pulmorenal syndrome, SLE and other collagenosis, thrombotic microangiopathy (HUS/TTP) and rheumatoid arthritis.
Collapse
|
11
|
de Groot K, Schreiber JG. [This is how I treat rheumatoid arthritis in dialysis patients]. Z Rheumatol 2023; 82:325-327. [PMID: 36853340 DOI: 10.1007/s00393-023-01334-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/27/2023] [Indexed: 03/01/2023]
Affiliation(s)
- Kirsten de Groot
- Medizinische Klinik 3, Sana Klinikum Offenbach, Starkenburgring 66, 63069, Offenbach, Deutschland
| | - Judith G Schreiber
- Medizinische Klinik 3, Sana Klinikum Offenbach, Starkenburgring 66, 63069, Offenbach, Deutschland.
| |
Collapse
|
12
|
Rajeshwari B, Kumar S. Rheumatoid Neuropathy: A Brief Overview. Cureus 2023; 15:e34127. [PMID: 36843697 PMCID: PMC9947570 DOI: 10.7759/cureus.34127] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2022] [Accepted: 01/23/2023] [Indexed: 01/25/2023] Open
Abstract
Rheumatoid arthritis is an autoimmune disease commonly found in humans. It is characterized by stiffness and swelling of the joints, along with fatigue and malaise. Rheumatoid neuropathy is a neuropathy that arises as a complication of rheumatoid arthritis. The primary objective of this review article is to provide a detailed account of the various aspects of this neurological complication ranging from its incidence, clinical features, and diagnosis. After searching through various published review articles and textbooks, rheumatoid neuropathy is one of the most common complications of rheumatoid arthritis. Out of all types of neuropathies. the most observed is entrapment neuropathy. Carpel tunnel syndrome is the most common type of entrapment neuropathy. There seems to be a greater predilection of rheumatoid neuropathy in females compared to males. A direct relation exists between rheumatoid factor and the occurrence of neuropathy. Some clinical features of rheumatoid neuropathy include stiffness in hands and feet, burning and tingling, stabbing pain, occasional weakness, and numbness in several cases. The common modalities of diagnosis are history, clinical examination, blood test, magnetic resonance imaging, nerve conduction study, and tissue biopsy. From the above-mentioned modalities, nerve conduction studies must be chosen as they can detect latent cases quickly and effective treatment can be initiated immediately. Finally, we outline the treatment plan for the disease which can be divided into medical and surgical management. Medical management consists of symptomatic treatment such as analgesics, anticonvulsants, and antidepressants, while surgical management is the last resort and consists of nerve compression.
Collapse
Affiliation(s)
- Bhavya Rajeshwari
- Department of Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND
| | - Sunil Kumar
- Department of Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND
| |
Collapse
|
13
|
[Ultrasound-targeted joint puncture in rheumatology]. Z Rheumatol 2022; 81:858-867. [PMID: 36197588 DOI: 10.1007/s00393-022-01269-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/30/2022] [Indexed: 12/13/2022]
Abstract
Joint punctures not only have a long tradition but are also an essential component in the diagnostic differentiation of various joint diseases. In addition, therapeutic injections are an essential component of an individual targeted treatment strategy in a disease-modifying antirheumatic drug (DMARD)-based treat-to-target concept. This article aims to convey to the reader the ultrasound-targeted joint puncture techniques in text and with many video clips that can be downloaded. This article therefore steps away from the conventional two-dimensional demonstration of anatomy-oriented puncture techniques and elucidates the diagnostic and therapeutic potency of ultrasound-targeted techniques in the daily routine. Furthermore, special importance is given to a sterile working technique, puncture material and synovial analysis.
Collapse
|
14
|
Freudenberg LS, Sewerin P, Ohlerth SM, Pomykala KL, Freudenberg S, Rischpler C, Lützen U. The future of radiosynoviorthesis: bright or bleak? THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING : OFFICIAL PUBLICATION OF THE ITALIAN ASSOCIATION OF NUCLEAR MEDICINE (AIMN) [AND] THE INTERNATIONAL ASSOCIATION OF RADIOPHARMACOLOGY (IAR), [AND] SECTION OF THE SOCIETY OF... 2022; 66:345-351. [PMID: 35708602 DOI: 10.23736/s1824-4785.22.03475-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Radiosynoviorthesis (RSO) is a decades known, effective intra-articular nuclear medicine local therapy, with few rare side-effects, in which inflamed synovial membrane is treated by means of colloidal beta-emitters. There are major variations worldwide in terms of acceptance, frequency of use and approved indications for this procedure. Thus, reliable figures that reflect reality are only available for a few countries. A Europe-wide survey revealed that RSO is carried out most frequently in Germany, where RSO is the most common nuclear medicine therapy with about 70,000 joints treated per year. The main indications include synovitis due to rheumatoid arthritis, hemophilia and pigmented villonodular synovitis (PVNS), and depending on national approvals, osteoarthritis. Despite the many indications, there are very few published scientific studies and therefore, RSO evidence is lacking. Reliable data on the clinical usage of RSO and demographics of RSO specialists are only available in Germany, thus we discuss the future challenges of RSO mainly from a German perspective. In the German healthcare system, RSO is performed primarily on an outpatient basis and plays only a minor role in the university setting. The necessary expertise for RSO is therefore lacking, for the most part, at university training centers. Currently, nearly more than three quarters of the German RSO experts are over fifty years old, illustrating a shortage of young talent. In the future, RSO providers from the non-university or private sector will have to cooperate with universities through networks and will have to intensify their cooperation with referring physicians, such as rheumatologist and orthopedic surgeons, and patients in order to maintain a timely and beneficial exchange of information. In networks of RSO experts, the participants must jointly develop and establish training concepts and facilities for future talents, elaborate on guidelines, if clinically useful expand the range of indications, initiate studies to generate further evidence and finally make the procedure more public. In addition, it is worthwhile to apply this process beyond human medicine to other fields, such as medical physics and veterinary medicine. If these points are implemented, the future of RSO will be bright, if it fails, it looks bleak.
Collapse
Affiliation(s)
- Lutz S Freudenberg
- ZRN Rheinland und ZRN MVZ GmbH, Korschenbroich, Germany -
- Exzellenznetzwerk RSO e.V., Langgöns, Germany -
- Department of Nuclear Medicine, University of Duisburg-Essen, Essen, Germany -
| | - Phillipp Sewerin
- Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany
| | - Stefanie M Ohlerth
- Clinic of Diagnostic Imaging, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland
| | - Kelsey L Pomykala
- Institution for Artificial Intelligence in Medicine (IKIM), University of Duisburg-Essen, Essen, Germany
| | | | - Christoph Rischpler
- Department of Nuclear Medicine, University of Duisburg-Essen, Essen, Germany
| | - Ulf Lützen
- Department of Nuclear Medicine University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
| |
Collapse
|
15
|
|
16
|
Kiltz U, Buschhorn-Milberger V, Albrecht K, Lakomek HJ, Lorenz HM, Rudwaleit M, Schneider M, Schulze-Koops H, Aringer M, Hasenbring MI, Herzer P, von Hinüber U, Krüger K, Lauterbach A, Manger B, Oltman R, Schuch F, Schmale-Grede R, Späthling-Mestekemper S, Zinke S, Braun J. [Development of quality standards for patients with rheumatoid arthritis for use in Germany]. Z Rheumatol 2022; 81:744-759. [PMID: 34652486 PMCID: PMC9646547 DOI: 10.1007/s00393-021-01093-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/17/2021] [Indexed: 10/20/2022]
Abstract
Despite a qualitatively and structurally good care of patients with rheumatoid arthritis (RA) in Germany, there are still potentially amendable deficits in the quality of care. For this reason, the German Society for Rheumatology (DGRh) has therefore decided to ask a group of experts including various stakeholders to develop quality standards (QS) for the care of patients with RA in order to improve the quality of care. The QS are used to determine and quantitatively measure the quality of care, subject to relevance and feasibility. The recently published NICE and ASAS standards and a systematic literature search were used as the basis for development. A total of 8 QS, now published for the first time, were approved with the intention to measure and further optimize the quality of care for patients with RA in Germany.
Collapse
Affiliation(s)
- U Kiltz
- Rheumazentrum Ruhrgebiet, Claudiusstr. 45, 44649, Herne, Deutschland.
- Ruhr-Universität Bochum, Bochum, Deutschland.
| | | | - K Albrecht
- Programmbereich Epidemiologie, Deutsches Rheuma-Forschungszentrum (DRFZ), Berlin, Deutschland
| | - H-J Lakomek
- Johannes-Wesling-Klinikum Minden, Universitätsklinik für Geriatrie, Minden, Deutschland
| | - H-M Lorenz
- Sektion Rheumatologie, Medizinische Klinik V, Universitätsklinikum Heidelberg, Universität Heidelberg, Heidelberg, Deutschland
| | - M Rudwaleit
- Universitätsklinik für Innere Medizin und Rheumatologie, Klinikum Bielefeld Rosenhöhe, Universität Bielefeld, Bielefeld, Deutschland
| | - M Schneider
- Poliklinik, Funktionsbereich und Hiller Forschungszentrum für Rheumatologie, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Deutschland
| | - H Schulze-Koops
- Sektion Rheumatologie und Klinische Immunologie, Medizinische Klinik und Poliklinik IV, LMU-Klinikum München, Ludwig-Maximilians-Universität München, München, Deutschland
| | - M Aringer
- Medizinische Klinik und Poliklinik III, Rheumatologie, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Deutschland
| | - M I Hasenbring
- Abteilung für Medizinische Psychologie und Medizinische Soziologie, Ruhr-Universität Bochum, Bochum, Deutschland
| | - P Herzer
- Medicover München MVZ, München, Deutschland
| | - U von Hinüber
- Praxis für Rheumatologie und Osteologie, Hildesheim, Deutschland
| | - K Krüger
- Rheumatologisches Praxiszentrum St. Bonifatius, München, Deutschland
| | - A Lauterbach
- Physiotherapieschule Friedrichsheim, Friedrichsheim, Deutschland
| | - B Manger
- Medizinische Klinik 3 Rheumatologie und Immunologie, Universitätsklinikum, Friedrich-Alexander-Universität Erlangen/Nürnberg, Erlangen, Deutschland
| | - R Oltman
- Hochschule für Gesundheit Bochum, Bochum, Deutschland
| | - F Schuch
- Rheumatologische Schwerpunktpraxis Erlangen, Erlangen, Deutschland
| | | | | | - S Zinke
- Rheumatologische Schwerpunktpraxis Zinke, Berlin, Deutschland
- Bundesverband Deutscher Rheumatologen e. V. (BDRh), Grünwald, Deutschland
| | - J Braun
- Rheumazentrum Ruhrgebiet, Claudiusstr. 45, 44649, Herne, Deutschland
- Ruhr-Universität Bochum, Bochum, Deutschland
| |
Collapse
|
17
|
Birkner B, Rech J, Edelmann E, Verheyen F, Schett G, Stargardt T. Patient-individual tapering of DMARDs in rheumatoid arthritis patients in a real-world setting. Rheumatology (Oxford) 2022; 62:1476-1484. [PMID: 35980267 DOI: 10.1093/rheumatology/keac472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2022] [Revised: 07/17/2022] [Accepted: 07/17/2022] [Indexed: 11/12/2022] Open
Abstract
OBJECTIVE We aim to provide real-world evidence on the effectiveness of patient-individual tapering of DMARDs for patients with rheumatoid arthritis (RA) in daily clinical practice using medical records and claims data. METHODS We utilize data obtained through a controlled prospective cohort study in Germany conducted from July 2018 to March 2021. Participants consist of RA patients in sustained remission (>6 months) who were eligible for tapering at enrolment. Patients treated with individual tapering based on shared decision making (n = 200) are compared with patients without any dose-reduction (n = 237). The risk of loss of remission and the risk of flare is assessed with risk-adjusted Kaplan-Meier estimators and Cox-Regressions. We evaluate differences in costs one year before and after baseline based on claims data for the subgroup of patients insured at one major sickness fund in Germany (n = 76). RESULTS The risk of flare (HR 0.88 95%-CI: 0.59-1.30) or loss of remission (HR 1.04 95%-CI: 0.73, 1.49) was not statistically different between the individual tapering group and the continuation group. Minor increases of disease activity and decreases of quality of life were observed 12 months after baseline, again with no statistically significant difference. Drug costs decreased by 1,017€in the individual tapering group while increased by 1,151€in the continuation group (p< 0.01). CONCLUSION Individual tapering of DMARDs does not increase the average risk of experiencing flares or loss of remission. Encouraging rheumatologists and patients to apply tapering in shared decision may be a feasible approach to allow individualisation of treatment in RA.
Collapse
Affiliation(s)
- Benjamin Birkner
- Hamburg Center for Health Economics (HCHE), Universität Hamburg, Hamburg, Germany
| | - Jürgen Rech
- Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany
| | | | | | - Georg Schett
- Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany
| | - Tom Stargardt
- Hamburg Center for Health Economics (HCHE), Universität Hamburg, Hamburg, Germany
| |
Collapse
|
18
|
Jeiziner C, Allemann SS, Hersberger KE, Meyer zu Schwabedissen HE. Is Pharmacogenetic Panel Testing Applicable to Low-Dose Methotrexate in Rheumatoid Arthritis? – A Case Report. Pharmgenomics Pers Med 2022; 15:465-475. [PMID: 35586477 PMCID: PMC9109898 DOI: 10.2147/pgpm.s354011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2021] [Accepted: 04/03/2022] [Indexed: 11/25/2022] Open
Abstract
Purpose Pharmacogenetic (PGx) panel testing could help to determine the heritable component of a rheumatoid arthritis (RA) patient’s susceptibility for therapy failure and/or adverse drug reactions (ADRs) from methotrexate (MTX). Considering the literature mentioning the potential applicability of PGx panel testing within MTX regimens, we discuss the case of a patient who was treated with MTX, suffered from ADRs, and obtained a reactive PGx panel testing. Genotyping We used a commercial PGx panel test involving the ABC-transporters P-glycoprotein (P-gp; gene: ABCB1), and breast cancer resistance protein (BCRP; gene: ABCG2), the solute carriers reduced folate carrier 1 (RFC1; gene: SLC19A1), and organic anion transporting polypeptide 1B1 (OATP1B1; gene: SLCO1B1), and the enzymes inosine triphosphatase (ITPA), and glutathione transferase P1 (GSTP1). In addition, we genotyped the patient for the enzymes 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase (AICAR)/inosine monophosphate (IMP) cyclohydrolase (gene name: ATIC), gamma-glutamyl hydrolase (gene name: GGH) and methylenetetrahydrofolate reductase (gene name: MTHFR). Results The PGx profile of the patient revealed genetic variants in SLC19A1, ABCB1, and MTHFR, which may explain the ADRs experienced during the treatment with MTX and a potentially lower efficacy of MTX. Based on our interpretation of the PGx profile, we recommended the patient to avoid MTX in the future. Conclusion The MTX pathway is complex, which makes the interpretation of genetic variants affecting metabolism challenging. A reactive PGx panel test was applicable to explain ADRs experienced during MTX treatment for a patient with RA. However, the clinical utility of PGx-guided MTX treatment in a primary care setting is still limited. In order to base a recommendation for MTX on PGx data, we need genome-wide association studies, large prospective multicenter studies and PGx studies, which analyze different multi-gene haplotypes and gene-drug-drug interactions for MTX.
Collapse
Affiliation(s)
- Chiara Jeiziner
- Pharmaceutical Care Research Group, Department Pharmaceutical Sciences, University of Basel, Basel, Switzerland
- Correspondence: Chiara Jeiziner, Pharmaceutical Care Research Group, Department Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, Basel, 4056, Switzerland, Tel +41 61 207 61 80, Email
| | - Samuel S Allemann
- Pharmaceutical Care Research Group, Department Pharmaceutical Sciences, University of Basel, Basel, Switzerland
| | - Kurt E Hersberger
- Pharmaceutical Care Research Group, Department Pharmaceutical Sciences, University of Basel, Basel, Switzerland
| | | |
Collapse
|
19
|
Klemm P, Müller-Ladner U, Lange U. Multimodale rheumatologische Komplexbehandlung. Z Rheumatol 2022; 81:369-375. [DOI: 10.1007/s00393-022-01181-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/29/2022] [Indexed: 01/12/2023]
|
20
|
Tony HP, Feist E, Aries PM, Zinke S, Krüger K, Ahlers J, Albrecht I, Barrionuevo C, Kalus S, Burkhardt H. Sarilumab reduces disease activity in rheumatoid arthritis patients with inadequate response to JAK-inhibitors or tocilizumab in regular care in Germany. Rheumatol Adv Pract 2022; 6:rkac002. [PMID: 35146322 PMCID: PMC8824706 DOI: 10.1093/rap/rkac002] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2021] [Accepted: 01/06/2022] [Indexed: 11/13/2022] Open
Abstract
Abstract
Objectives
To evaluate safety and effectiveness of sarilumab in rheumatoid arthritis (RA) patients after inadequate response (IR) to janus kinase inhibitors (JAKi) and tocilizumab.
Methods
The prospective, observational, 24-months single-arm PROSARA study (SARILL08661) is currently running in Germany at 96 sites. RA patients were prospectively selected at physician’s discretion according to label. This interim analysis (IA) included 536 patients over a treatment course of up to 6 months. Patients were stratified in 4 groups according to pretreatment before start of sarilumab therapy: 1. last prior treatment JAKi (JAKi-IR), 2. last prior treatment tocilizumab (tocilizumab-IR), 3. any other biological disease-modifying antirheumatic drug (bDMARD) in treatment history (bDMARD TH) and 4. patients who haven’t received any bDMARDs or targeted synthetic (ts) DMARDs (b/tsDMARD naïve) before.
Results
For this pre-planned IA, 536 patients were included in the baseline population, of which 502 patients had at least one corresponding post-baseline effectiveness assessment documented (main analysis population). In all analysed cohorts, safety was consistent with the anticipated profile of sarilumab, without new safety signals. Six months of sarilumab treatment attenuated disease activity in JAKi-IR, tocilizumab-IR, bDMARD TH and b/tsDMARD naïve patients to a very similar extent. Physical function did not substantially change over the course of treatment. Premature study discontinuation rates were comparable between cohorts.
Conclusion
Sarilumab treatment was effective in patients with IR to JAKi and tocilizumab with an expectable safety profile and drug retention over 6 months. Confirmation of this promising results should encourage further studies on this treatment sequence which is highly practically relevant.
Study registration
Paul-Ehrlich-Institut—Federal Institute for Vaccine and Biomedics, SARILL08661
Collapse
Affiliation(s)
- Hans-Peter Tony
- Department of Internal Medicine 2, Universitätsklinikum Würzburg, Würzburg, Germany
| | - Eugen Feist
- Rheumatology and Clinical Immunology, HELIOS Fachklinik Vogelsang/Gommern, Vogelsang, Germany
| | | | - Silke Zinke
- Rheumatologische Schwerpunktpraxis, Berlin, Germany
| | - Klaus Krüger
- Rheumatology Medical Center St. Bonifatius, München, Germany
| | - Jonas Ahlers
- Sanofi-Aventis Deutschland GmbH, Berlin, Germany
| | | | | | - Stefanie Kalus
- GKM Gesellschaft für Therapieforschung mbH, München, Germany
| | - Harald Burkhardt
- Division of Rheumatology/CIRI, Universitätsklinikum Frankfurt, Frankfurt am Main, Germany
| |
Collapse
|
21
|
Mucke J, Simon HU, Rüdiger Burmester G. The Safety of Antirheumatic Drugs. DEUTSCHES ÄRZTEBLATT INTERNATIONAL 2022; 119. [PMCID: PMC9073170 DOI: 10.3238/arztebl.m2022.0064] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/25/2021] [Accepted: 11/22/2021] [Indexed: 05/21/2023]
Abstract
Background Drug therapy for rheumatic diseases has changed fundamentally in recent decades with the introduction of many new agents. As these drugs may have to be taken for many years, and many of them are of similar efficacy, the safety profiles of the individual substances play an important role in therapeutic decision-making. Method This review is based on pertinent literature retrieved by a selective search on the safety profiles of selected antirheumatic drugs. Results Non-steroidal antirheumatic drugs, glucocorticoids, conventional disease-modifying drugs such as methotrexate, biological agents, and janus kinase (JAK) inhibitors are all used to treat rheumatic diseases. Register and trial data show that antirheumatic treatments are relatively safe. Infections, in particular, are much less common than initially expected. Cortisone administration is an exception because of its severe long-term sequelae. Biological agents are associated with severe infectious events at a rate of 4–5 events per 100 patient years. Screening before treatment with biological agents has been shown to lower the rate of tuberculosis from 564 to 95 cases per 100 000 patient years. JAK inhibitors have a good safety profile, with respect to infections as well, but there is evidence of their association with cardiovascular problems, malignancies, and thrombosis. Conclusion A suitable, safe antirheumatic drug can be chosen for each patient in consideration of individual risk profiles. Regular monitoring enables the early detection of adverse effects. The risk profile of JAK inhibitors, in particular, will be studied in further trials.
Collapse
Affiliation(s)
- Johanna Mucke
- Policlinic and Hiller Research Unit for Rheumatology, University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf
| | - Hans-Uwe Simon
- Institute of Pharmacology, University of Bern
- Institute of Biochemistry, Brandenburg Medical School, Neuruppin
- Department of Clinical Immunology and Allergology, Sechenov University, Moscow, Russia
- Institute of Fundamental Medicine and Biology, Kazan University, Russia
| | - Gerd Rüdiger Burmester
- Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Freie Universität Berlin und Humboldt-Universität zu Berlin
- *Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie, Charité – Universitätsmedizin Berlin, Freie Universität Berlin und Humboldt-Universität zu Berlin Charitéplatz 1, 10117 Berlin, Germany
| |
Collapse
|
22
|
Abstract
Biologics are an integral part of modern strategies for treatment of rheumatoid arthritis (RA) and spondylarthritis (SpA), including psoriatic arthritis (PsA). Biologics are biotechnologically produced proteins that have inhibiting effects on humoral and cellular components of rheumatic inflammation. Substance classes used in rheumatology are tumor necrosis factor (TNF)-alpha, interleukin (IL)-1, IL‑6, IL-12, IL-17 and IL-23 inhibitors effective against cytokines as well as the T lymphocyte activation inhibitor abatacept and the B lymphocyte-depleting rituximab. There are clear recommendations for the use of biologics for RA patients inadequately responding to one or more conventional synthetic disease-modifying antirheumatic drugs and for ankylosing spondylitis (AS) and nonradiographical axial SpA patients with an inadequate response to at least two nonsteroidal antirheumatic drugs. For PsA the recommended use depends on the most prominent manifestations in each case. Treatment with biologics should follow the treat to target principle, with a defined and validated treatment target. Treatment in cases of RA and SpA should target remission or at least a low or minimum disease activity. The safety of treatment with biologics has been intensively investigated. There are very specific contraindications for individual substance classes with a focus on an increased risk of infections. The standard procedure before starting treatment with biologics includes the exclusion of latent tuberculosis and hepatitis B. The TNF-alpha inhibitors have a protective effect with respect to myocardial infarction, stroke and venous thromboembolism.
Collapse
|
23
|
[Innovative strategies for treatment of rheumatoid arthritis]. Z Rheumatol 2022; 81:118-124. [PMID: 34997270 DOI: 10.1007/s00393-021-01144-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/05/2021] [Indexed: 10/19/2022]
Abstract
Besides excellent guidelines and newly developed highly effective drugs, evidence-based strategic use of these new drugs has especially contributed to enormous advances in rheumatoid arthritis treatment, apparent especially since 2000. Currently, the treat-to-target (T2T) strategy has proven to be the most successful in several studies and systematic reviews. The target is to achieve remission, which should be reached and sustained for an optimal outcome (i.e. stable over a long time period). If the initial disease-modifying antirheumatic drug (DMARD) treatment fails, the best strategy for continuing treatment is controversial, with swap or switch being open to debate (change within a class of drugs or change in the mechanism of action). Recent studies seem to indicate that switching to another mechanism of action is the most successful approach. A hotly discussed topic is the question whether DMARD treatment can or should be tapered when sustained remission has been achieved? Many patients wish for a reduction of drugs in cases of stable remission; however, the stable disease control might become destabilized by tapering. The main priority is the reduction or tapering of glucocorticoid treatment. When the decision for reduction of DMARD treatment is made together with the patient, a complete cessation bears a high risk of a flare, therefore, a careful step by step reduction of DMARD treatment should be preferred. In the case of a running combination, the question whether the conventional DMARD (mostly methotrexate), the biological (b)DMARD or targeted synthetic (ts)DMARD should be reduced first, must be decided on an individual basis. Most patients prefer to first reduce methotrexate and transfer to a monotherapy.
Collapse
|
24
|
Oelzner P, Eidner T, Pfeil A. [Glucocorticoid-induced osteoporosis-Focus treatment (part 1)]. Z Rheumatol 2022; 81:57-66. [PMID: 34994812 DOI: 10.1007/s00393-021-01127-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/27/2021] [Indexed: 10/19/2022]
Abstract
With a fracture prevalence of 30-50%, glucocorticoid (GC)-induced osteoporosis is one of the most important comorbidities in inflammatory rheumatic diseases. Because of a reduction of bone quality with a lack of correlation with bone mineral density, the fracture risk during long-term GC treatment is not sufficiently represented by the currently available methods of osteodensitometry and therefore underestimated. According to the Confederation for Osteology (DVO) guidelines, a baseline osteological diagnosis including osteodensitometry is indicated in all postmenopausal women and in men aged 60 years and older who receive or are scheduled to receive GC at a dose of ≥ 2.5 mg prednisolone equivalent/day for > 3 months. Basic measures in GC-treated patients include vitamin D and calcium supplementation as well as measures to promote muscle strength and coordination and to prevent falls. The indications for a specific osteological treatment depend on the calculated GC dose, age, sex, and other fracture risk factors in addition to bone mineral density and prevalent fractures.
Collapse
Affiliation(s)
- Peter Oelzner
- Funktionsbereich Rheumatologie und Osteologie, Klinik für Innere Medizin III, Universitätsklinikum Jena, Am Klinikum 1, 07740, Jena, Deutschland.
| | - T Eidner
- Funktionsbereich Rheumatologie und Osteologie, Klinik für Innere Medizin III, Universitätsklinikum Jena, Am Klinikum 1, 07740, Jena, Deutschland
| | - A Pfeil
- Funktionsbereich Rheumatologie und Osteologie, Klinik für Innere Medizin III, Universitätsklinikum Jena, Am Klinikum 1, 07740, Jena, Deutschland
| |
Collapse
|
25
|
Hasseli R, Ladner UM. [COVID-19 and inflammatory rheumatic diseases]. Dtsch Med Wochenschr 2021; 146:1564-1568. [PMID: 34826845 DOI: 10.1055/a-1616-8742] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
Older age, cardiovascular comorbidities, chronic lung diseases, and GC use were identified as independent risk factors for severe courses of COVID-19 resulting in the need of hospitalization. Glucocorticoid dosis of > 10 mg over a longer period of time should be very carefully used as there are various immunomodulatory alternatives. Of particular note, disease activity of inflammatory rheumatic diseases (IRD) was also identified as an independent predictor of COVID-19 related hospitalization.Already in the early phase of the pandemic case reports of fatal courses of IRD patients under treatment with rituximab were reported. Meanwhile, several data could demonstrate higher rates of hospitalization and COVID-19-related deaths. Whether a similar effect is detectable regarding Janus kinase inhibitors in patients with rheumatoid arthritis is currently under investigation.Preliminary data indicate that all available COVID-19 vaccines in Europe are not associated with higher rates of disease flares or differences of side effect profiles compared to the general population. There is no recommendation to discontinue or reduce immunomodulatory treatment in general to achieve better immune response. In the case of Rituximab, consideration should be given to postponing or switching to alternative therapies, taking into account the risk of reactivation of the underlying disease on the one hand and the improvement of a potential vaccine response on the other.
Collapse
Affiliation(s)
- Rebecca Hasseli
- Abteilung für Rheumatologie und klinische Immunologie. Justus-Liebig-Universität Gießen, Campus Kerckhoff Bad Nauheim
| | - Ulf Müller Ladner
- Abteilung für Rheumatologie und klinische Immunologie. Justus-Liebig-Universität Gießen, Campus Kerckhoff Bad Nauheim
| |
Collapse
|
26
|
Haas JP, Weimann V, Feist E. [Polyarticular juvenile idiopathic arthritis and rheumatoid arthritis : Common features and differences]. Z Rheumatol 2021; 81:4-13. [PMID: 34713333 DOI: 10.1007/s00393-021-01114-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/31/2021] [Indexed: 10/20/2022]
Abstract
The spectrum of polyarthritic diseases in childhood as well as in adulthood is wide. In the differential diagnostics different age-related diseases must be taken into consideration. Although, a clear similarity is obvious in all age groups for the classical diseases of polyarticular juvenile idiopathic arthritis and rheumatoid arthritis with respect to the pathogenesis, clinical manifestation and treatment options, this review points to specific differences. The prognosis of polyarthritis in children mainly depends on the joint manifestation, whereas extra-articular comorbidities play a predominant role in the older adult population.
Collapse
Affiliation(s)
- Johannes-Peter Haas
- Deutsches Zentrum für Kinder- und Jugendrheumatologie, Zentrum für Schmerztherapie junger Menschen, Kinderklinik Garmisch-Partenkirchen gGmbH, Gehfeldstr. 24, 82467, Garmisch-Partenkirchen, Deutschland.
| | - Vincent Weimann
- Rheumatologie, Helios Fachklinik Vogelsang-Gommern, Vogelsang-Gommern, Deutschland
| | - Eugen Feist
- Rheumatologie, Helios Fachklinik Vogelsang-Gommern, Vogelsang-Gommern, Deutschland
| |
Collapse
|
27
|
Meyer-Olson D, Hoeper K. [Rehabilitation in Rheumatoid Arthritis]. REHABILITATION 2021; 60:339-354. [PMID: 34655068 DOI: 10.1055/a-1275-2657] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
Die rheumatoide Arthritis stellt unter den Erkrankungen des Bewegungssystems eine
besondere Herausforderung für die Rehabilitationsmedizin dar 1. Eine genaue Kenntnis der Erkrankung,
inklusive der medikamentösen und der nicht medikamentösen
Behandlungsoptionen, ist die wesentliche Voraussetzung für einen
nachhaltigen Rehabilitationserfolg und um den berechtigen Anspruch der
Erkrankten auf berufliche und soziale Partizipation umzusetzen.
Collapse
|
28
|
Seoudy AK, Beckmann A, Wietzke-Braun P, Settgast U, Ziegenbruch U, Türk K, Hartmann K, Brandes J, Schulte DM, Wehkamp K, Trettow M, Schreiber S, Laudes M. Tagesklinische Versorgungsstruktur zur Komplextherapie der Adipositas III°. DIABETOL STOFFWECHS 2021. [DOI: 10.1055/a-1482-8115] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Zusammenfassung
Hintergrund Die konservativen Behandlungsmöglichkeiten der Adipositas III° (BMI ≥ 40 kg/m2) sind limitiert, da flächendeckend eine adäquate Versorgungsstruktur nicht vorgehalten wird. Am Universitätsklinikum Schleswig-Holstein, Campus Kiel, wurde 2018 eine Tagesklinik zur Komplextherapie der Adipositas III° eingerichtet mit Sicherung der Finanzierung durch die Kostenträger über Tagessätze gemäß Krankenhausentgeltgesetz.
Methode Von 201 Adipositaspatienten, die sich von Juni 2018 bis Mai 2020 vorstellten, wurde die Tagesklinikbehandlung analysiert und zusätzlich wurde das Körpergewicht ein Jahr später ausgewertet.
Ergebnisse Die Komplextherapie fand in wöchentlichen Behandlungseinheiten über 26 Wochen statt. 170 von 201 Patienten haben die Behandlung komplettiert, entsprechend einer Adhärenzquote von 84,6 %. Das mediane Alter betrug 46 Jahre. Die Mehrheit der Patienten war weiblichen Geschlechts (64,7 %). In der Gruppe der Responder (≥ 10 % Gewichtsreduktion) betrug die absolute Gewichtsabnahme 27,1 kg entsprechend etwa 20 %. Auch die Non-Responder (< 10 %) konnten ihr Körpergewicht um 8,8 kg reduzieren; in dieser Gruppe fand sich ein signifikant höherer Frauenanteil (81,3 % vs. 60,9 %, p = 0,039). Responder und Non-Responder unterschieden sich hinsichtlich des Bauch- und Hüftumfangs sowie der Fettmasse (p-Wert jeweils < 0,001). Am Therapieende wiesen die Responder niedrigere Triglyzerid- (p = 0,019) und HbA1c-Konzentrationen (p = 0,030) auf. Ein Jahr nach Beginn der Komplextherapie imponierte eine stabile Gewichtsreduktion in beiden Gruppen.
Schlussfolgerung Die teilstationäre Adipositas-Komplextherapie in einer internistischen Tagesklinik stellt eine effektive Methode zur anhaltenden Gewichtsreduktion von Patienten mit Adipositas III° dar.
Collapse
Affiliation(s)
| | - Alexia Beckmann
- Medizinische Klinik 1, Universitätsklinikum Schleswig-Holstein, Kiel, Germany
| | | | - Ute Settgast
- Medizinische Klinik 1, Universitätsklinikum Schleswig-Holstein, Kiel, Germany
| | - Ursula Ziegenbruch
- Medizinische Klinik 1, Universitätsklinikum Schleswig-Holstein, Kiel, Germany
| | - Kathrin Türk
- Medizinische Klinik 1, Universitätsklinikum Schleswig-Holstein, Kiel, Germany
| | - Katharina Hartmann
- Medizinische Klinik 1, Universitätsklinikum Schleswig-Holstein, Kiel, Germany
| | - Juliane Brandes
- Medizinische Klinik 1, Universitätsklinikum Schleswig-Holstein, Kiel, Germany
| | | | - Kai Wehkamp
- Medizinische Klinik 1, Universitätsklinikum Schleswig-Holstein, Kiel, Germany
| | - Marc Trettow
- Medizinische Klinik 1, Universitätsklinikum Schleswig-Holstein, Kiel, Germany
| | - Stefan Schreiber
- Medizinische Klinik 1, Universitätsklinikum Schleswig-Holstein, Kiel, Germany
| | - Matthias Laudes
- Medizinische Klinik 1, Universitätsklinikum Schleswig-Holstein, Kiel, Germany
| |
Collapse
|
29
|
Froschauer S, Muth T, Bredow L, Feist E, Heinemann-Dammann SP, Zinke S, Fiehn C. [Care atlas rheumatology : Approaches and concepts for improving care in outpatient rheumatology]. Z Rheumatol 2021; 80:819-826. [PMID: 34535817 DOI: 10.1007/s00393-021-01072-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/30/2021] [Indexed: 11/26/2022]
Abstract
Inflammatory rheumatic diseases affect 1.5 million adults and an estimated 20,000 children and adolescents throughout Germany. The successful treatment of these patients is largely based on the availability of high-quality medical care. To be able to provide sufficient care and prevent long waiting times even though the number of rheumatologists is below demand, efficient practice structures and approaches that go beyond standard care play an important role. The present study takes a look at the current state of rheumatological outpatient care as well as innovative care initiatives to support the service provision structures and to improve the care situation in rheumatology and points out: to ensure guideline-based care despite scarce resources, selective contracts, integrated outpatient specialist care (ASV), early or emergency consultation hours, disease management programs (DMP) and appropriate delegation of medical services play an important role. New care concepts increasingly focus on interdisciplinary cooperation (DMP and ASV), strengthened self-management through structured patient training (DMP) and targeted patient management through screening tools. To ensure an up to date and high-quality treatment in the long term, an increase in further training in rheumatology is necessary. This should be achieved by attracting more students and, if necessary, adjusting the training system.
Collapse
Affiliation(s)
- Sonja Froschauer
- Berufsverband Deutscher Rheumatologen e. V., Dr.-Max-Str. 21, 82031, Grünwald, Deutschland.
| | | | | | - Eugen Feist
- Rheumatologie, Helios Fachklinik Vogelsang-Gommern, Vogelsang-Gommern, Deutschland
| | | | - Silke Zinke
- Rheumatologische Schwerpunktpraxis, Berlin, Deutschland
| | - Christoph Fiehn
- Rheumatologie Baden-Baden GbR, Tätigkeitsschwerpunkt Klinische Immunologie, Medical Center Baden-Baden, Baden-Baden, Deutschland
| |
Collapse
|
30
|
Hartmann AM, Dell'Oro M, Kessler CS, Schumann D, Steckhan N, Jeitler M, Fischer JM, Spoo M, Kriegel MA, Schneider JG, Häupl T, Kandil FI, Michalsen A, Koppold-Liebscher DA. Efficacy of therapeutic fasting and plant-based diet in patients with rheumatoid arthritis (NutriFast): study protocol for a randomised controlled clinical trial. BMJ Open 2021; 11:e047758. [PMID: 34380725 PMCID: PMC8359474 DOI: 10.1136/bmjopen-2020-047758] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND Previous studies have shown beneficial effects of therapeutic fasting and plant-based dietary interventions on disease activity in patients with rheumatoid arthritis (RA) for a duration of up to 1 year. To date, the effects of such interventions on the gut microbiome and on modern diagnostic markers in patients with RA have not been studied. This trial aims to investigate the clinical effects of therapeutic fasting and a plant-based diet in patients with RA, additionally considering current immunological diagnostic tools and microbiome analyses. METHODS/DESIGN This trial is an open-label, single-centre, randomised, controlled, parallel-group clinical trial. We will randomly assign 84 patients with RA under a stable standard therapy to either (1) therapeutic fasting followed by a plant-based dietary intervention or (2) to a conventional nutritional counselling focusing on an anti-inflammatory dietary pattern according to the recommendations of the Deutsche Gesellschaft für Ernährung (German society for nutrition). Primary outcome parameter is the group difference from baseline to 12 weeks on the Health Assessment Questionnaire (HAQ). Other secondary outcomes include established clinical criteria for disease activity and treatment response in RA (Disease Activity Score 28, Simple Disease Activity Index, ACR-Response Criteria), changes in self-reported health and physical functional ability, mood, stress, quality of life, dietary behaviour via 3-day food records and a modified Food Frequency Questionnaire, body composition, changes in the gut microbiome, metabolomics and cytometric parameters. Outcomes will be assessed at baseline and day 7, after 6 weeks, 12 weeks and after 6 months. ETHICS AND DISSEMINATION Ethical approval to process and analyse data, and to publish the results was obtained through the institutional review board of Charité-Universitätsmedizin Berlin. Results of this trial will be disseminated through peer-reviewed publications and scientific presentations. TRIAL REGISTRATION NUMBER NCT03856190.
Collapse
Affiliation(s)
- Anika M Hartmann
- Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - Melanie Dell'Oro
- Department of Internal and Integrative Medicine, Immanuel Hospital Berlin-Wannsee Branch, Berlin, Germany
| | - Christian S Kessler
- Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- Department of Internal and Integrative Medicine, Immanuel Hospital Berlin-Wannsee Branch, Berlin, Germany
| | - Dania Schumann
- Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - Nico Steckhan
- Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - Michael Jeitler
- Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- Department of Internal and Integrative Medicine, Immanuel Hospital Berlin-Wannsee Branch, Berlin, Germany
| | - Jan Moritz Fischer
- Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - Michaela Spoo
- Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- Department of Internal and Integrative Medicine, Immanuel Hospital Berlin-Wannsee Branch, Berlin, Germany
| | - Martin A Kriegel
- Institute for Musculoskeletal Medicine, Department of Translational Rheumatology and Immunology, University of Münster, Münster, Germany
- Department of Immunobiology, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Jochen G Schneider
- Department of Internal Medicine II, Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes, Homburg, Germany
- Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Luxembourg, Luxembourg
| | - Thomas Häupl
- Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - Farid I Kandil
- Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- Department of Neurology, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - Andreas Michalsen
- Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- Department of Internal and Integrative Medicine, Immanuel Hospital Berlin-Wannsee Branch, Berlin, Germany
| | - Daniela A Koppold-Liebscher
- Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| |
Collapse
|
31
|
Schwarze M, Fieguth V, Schuch F, Sandner P, Edelmann E, Händel A, Kettler M, Hanke A, Kück M, Stein L, Stille C, Fellner M, De Angelis V, Touissant S, Specker C. [Disease-related knowledge acquisition through structured patient information in rheumatoid arthritis (StruPI-RA) : First results of the StruPI-RA study in Germany]. Z Rheumatol 2021; 80:364-372. [PMID: 32926219 PMCID: PMC8096752 DOI: 10.1007/s00393-020-00871-7] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/28/2020] [Indexed: 02/07/2023]
Abstract
BACKGROUND/OBJECTIVE The structured patient information for rheumatoid arthritis (StruPi-RA) program was the first standardized outpatient education program in rheumatoid arthritis (RA) in Germany. The main objective of the study was to determine the efficacy of the StruPi-RA program concerning disease-specific knowledge acquisition in patients with early stage RA or after changing the treatment regimen. METHODS A total of 61 patients were included in a control group design, 32 in the intervention group (IG) and 29 in the control group (CG). Patients of the IG attended 3 modules of 90 min in a structured patient information program (StruPI-RA) including the topics of diagnostics, treatment and living with RA. Patients in the CG only received information material from the German Rheumatism League. The primary target criterion was the disease-related acquisition of knowledge, measured with the patient knowledge questionnaire (PKQ). Data were collected before and after participation in StruPI-RA. RESULTS The improvement in knowledge in the IG attending the StruPI-RA compared to the CG was significant in time and group comparisons. No influence of disease duration or educational level was observed. The subscale treatment alone showed a significant difference in the group and time comparison. CONCLUSION Participation in the StruPI-RA program in early RA was associated with a significant increase in disease-specific knowledge compared to the control group of patients. This leads to better decision-making in terms of treatment, a more beneficial doctor-patient communication and better self-management. In the long term an improvement in treatment adherence and quality of life is expected.
Collapse
Affiliation(s)
- M Schwarze
- Institut für Sportmedizin, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland.
| | - V Fieguth
- Institut für Sportmedizin, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland
| | - F Schuch
- Rheumatologische Schwerpunktpraxis, Erlangen, Deutschland
| | - P Sandner
- Rheumatologische Schwerpunktpraxis, Erlangen, Deutschland
| | - E Edelmann
- Rheumazentrum Bad Aibling-Erding, Bad Aibling, Deutschland
| | - A Händel
- Rheumazentrum Bad Aibling-Erding, Bad Aibling, Deutschland
| | - M Kettler
- Institut für Sportmedizin, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland
| | - A Hanke
- Institut für Sportmedizin, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland
| | - M Kück
- Institut für Sportmedizin, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland
| | - L Stein
- Institut für Sportmedizin, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland
| | - C Stille
- Rheumatologie-Praxis, Hannover, Deutschland
| | - M Fellner
- Rheumatologie-Praxis, Hannover, Deutschland
| | | | - S Touissant
- Rheumatologie Centrum, Leverkusen, Deutschland
| | - C Specker
- Klinik für Rheumatologie & Klinische Immunologie, Kliniken Essen-Mitte, Essen, Deutschland
- Arbeitsgemeinschaft Regionaler Kooperativer Rheumazentren in der Deutschen Gesellschaft für Rheumatologie e. V. (DGRh), Berlin, Deutschland
| |
Collapse
|
32
|
[Arthralgia with detection of anti-CCP antibodies : Which treatment options exist?]. Z Rheumatol 2021; 80:487-488. [PMID: 33791848 DOI: 10.1007/s00393-021-00992-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/06/2021] [Indexed: 10/21/2022]
|
33
|
Tschirschwitz B, Keyßer G. Wie häufig sind unkomplizierte Infektionen in der ambulanten Rheumaversorgung? Ergebnisse einer Befragung von Patienten mit rheumatischen Erkrankungen. AKTUEL RHEUMATOL 2021. [DOI: 10.1055/a-1371-1338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Zusammenfassung
Hintergrund Patienten mit entzündlich-rheumatischen Erkrankungen haben ein erhöhtes Infektionsrisiko. Nicht nur die Erkrankung selbst, sondern auch die antirheumatische Therapie spielt dabei eine wichtige Rolle. Ziel dieser Arbeit war die Untersuchung der Häufigkeit unkomplizierter Infektionen und die Suche nach einem möglichem Underreporting derartiger Ereignisse. Geklärt werden sollte die Sichtweise der Patienten in Bezug auf das Infektionsrisiko sowie die Frage, ob unterschiedliche Therapien im klinischen Alltag messbar zu unterschiedlichen Infektionsraten führen.
Material und Methoden Zwischen 2013 und 2014 erfolgte im Raum Halle-Leipzig eine anonymisierte Patientenbefragung von 590 ambulant betreuten Patienten mit einer mindestens 2 Jahre andauernden rheumatologischen Erkrankung.
Ergebnisse Die Rate beantworteter Fragebögen betrug 78%. Daten von 432 Patienten (68% weiblich; Durchschnittsalter 55±14 Jahre) wurden ausgewertet (48% rheumatoide Arthritis). 66% der Patienten berichteten durchschnittlich 2 unkomplizierte Infektionen pro Jahr. Am häufigsten traten Atemwegsinfektionen auf (40%). 82% der Infektionen wurden ärztlich behandelt, davon jede fünfte von einem Rheumatologen. Mindestens 12% aller Infektionen wurden nicht ärztlich erfasst. Eine Biologica-Therapie erhöhte weder die Häufigkeit noch den Schweregrad von unkomplizierten Infektionen signifikant, verglichen mit konventionellen DMARDs. Die Mehrheit der Patienten unter bDMARDs sahen in dieser Therapie keine Nachteile. 58% verneinten, durch die Einnahme von Biologica häufiger unter Infektionen zu leiden. Mehr als 60% der Patienten sahen keinen Zusammenhang zwischen den Infektionen und ihrer aktuellen Medikation. Lediglich 16% der Patienten hielten eine erhöhte Infektanfälligkeit für bedenklich.
Schlussfolgerung Unkomplizierte Infektionen sind bei ambulant betreuten Rheumatikern häufig, verursachen aber offenbar wenig Probleme. Infektionen spielen im Bewusstsein der Patienten im Vergleich zu anderen unerwünschten Nebenwirkungen nicht die wichtigste Rolle. Ein vermehrtes Auftreten von unkomplizierten Infektionen unter bDMARDs konnte nicht gezeigt werden.
Collapse
Affiliation(s)
- Benjamin Tschirschwitz
- Klinik für Anästhesiologie und Intensivmedizin, Notfallmedizin und Schmerztherapie, Städtisches Klinikum Dresden, Dresden, Deutschland
| | - Gernot Keyßer
- Department für Innere Medizin, Klinik und Poliklinik für Innere Medizin II, Universitätsklinikum Halle (Saale), Halle (Saale), Deutschland
| |
Collapse
|
34
|
[Safety aspects of the treatment with glucocorticoids for rheumatoid arthritis]. Z Rheumatol 2021; 80:295-304. [PMID: 33704557 PMCID: PMC7948162 DOI: 10.1007/s00393-021-00972-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/28/2020] [Indexed: 12/15/2022]
Abstract
Glukokortikoide (GC) werden für die initiale Therapie der RA nach wie vor empfohlen – zeitlich befristet und in geringstmöglicher Dosierung. Ihre komplexe Wirkweise geht mit Nebenwirkungen einher, die v. a. in der Dauertherapie oberhalb von 5 mg Prednisolon pro Tag eine Rolle spielen. In diesem Dosisbereich begünstigen sie Osteoporose, Diabetes/Hyperglykämie, kardiovaskuläre Ereignisse und Infektionen und tragen damit zu einer vermehrten Frühsterblichkeit bei. Dabei sind die Risiken der GC-Therapie von patientenbezogenen Faktoren abhängig wie Alter, Komorbidität und Begleitmedikation. Ein negativer Einfluss sehr niedriger Steroiddosen auf das Gesamtüberleben ist möglicherweise bei hoher kumulativer Dosis nachweisbar, die Datenlage ist hier jedoch widersprüchlich. Das Monitoring einer GC-vermittelten Toxizität mithilfe eines validierten Index sollte in Zukunft dazu beitragen, die Vorteile einer steroidsparenden Behandlungsstrategie besser zu beschreiben. Selektiver wirkende Substanzen könnten in Zukunft eine Abkopplung der erwünschten Wirkungen von den Nebenwirkungen ermöglichen.
Collapse
|
35
|
Fiehn C. [Glucocorticoid-free and low-dose glucocorticoid treatment of rheumatoid arthritis]. Z Rheumatol 2021; 80:305-313. [PMID: 33689031 DOI: 10.1007/s00393-021-00973-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/29/2021] [Indexed: 11/26/2022]
Abstract
Systemic glucocorticoids (GC) are a commonly used component in the treatment of rheumatoid arthritis. The aim of this article is to show the evidence for low-dose GC or GC-free RA treatment regimens. Furthermore, concepts for the de-escalation of GC treatment for RA are presented. There is sufficient evidence in the initial phase that GC treatment in addition to methotrexate (MTX) improves the patient's response to the disease activity as well as the subjective perception of impairments. The dosage of GC, however, needs to be weighed critically and the guideline-based gradual reduction leading eventually to discontinuation must consistently be pursued. In the later phases of the treatment algorithm the risks of GC administration outweigh the benefits and long-term GC treatment should therefore be reserved for exceptional cases. The lowest possible dosage always needs to be determined individually. This can be achieved by using a clinically tested scheme of reducing the prednisolone intake by 1 mg every 4 weeks. The scheme should be considered for patients with a low disease activity or remission due to disease-modifying antirheumatic drug (DMARD) treatment, if they receive 5 mg of prednisolone as long-term treatment. On the whole the positive subjective effects of GC treatment must always be weighed up against the risks of such treatment for RA patients. An ongoing process of readjusting treatment following shared-decision rules must both consistently adapt GC doses and constantly check the indications. Even if a GC-free treatment does not seem realistic, a low-dose GC treatment of RA still is and should be pursued to reduce the risks associated with the treatment.
Collapse
Affiliation(s)
- Christoph Fiehn
- Rheumatologie Baden-Baden Tätigkeitsschwerpunkt klinische Immunologie, Medical Center, Beethovenstr. 2, 76530, Baden-Baden, Deutschland.
| |
Collapse
|
36
|
[59/f-Increasing swelling of the right wrist : Preparation for the medical specialist examination: part 21]. Internist (Berl) 2021; 62:118-124. [PMID: 33656568 DOI: 10.1007/s00108-021-00973-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/26/2021] [Indexed: 10/22/2022]
|
37
|
Methotrexate does not increase the risk of liver fibrosis in patients with rheumatoid arthritis: assessment by ultrasound elastography (ARFI-MetRA study). Rheumatol Int 2021; 41:1079-1087. [PMID: 33608744 DOI: 10.1007/s00296-021-04804-8] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2020] [Accepted: 02/02/2021] [Indexed: 10/22/2022]
Abstract
OBJECTIVES Only limited data are available on the risk of liver fibrosis in patients with rheumatoid arthritis on long-term methotrexate treatment. To assess the risk of liver fibrosis in patients with rheumatoid arthritis treated with methotrexate, non-invasive, ultrasound-based elastography [acoustic radiation force impulse (ARFI) imaging] was applied. METHODS In total, 119 patients were assessed using acoustic radiation force impulse (ARFI) imaging between July 2018 and April 2019. In a cross-sectional, single-centre study design, ARFI scores were compared between patient subgroups with (n = 65) and without (n = 54) methotrexate exposure. The main outcome variable was the mean fibrosis score as measured by the ARFI method. The mean shear wave velocity was calculated from 10 valid ARFI measurements for each patient. Inferential statistical analyses (between group) were performed using ANOVA for independent samples in the case of continuous outcome variables. RESULTS Sixty-five patients with and fifty-four patients without MTX exposure were assessed using the ARFI elastography method. Participating patients on MTX medication (1.113 m/s) showed ARFI scores that were comparable to those of participants without MTX exposure (1.062 m/s); P = 0.228. The mean cumulative dose in the group of MTX-exposed patients was 3602 mg. CONCLUSION The mean value of the repeated determination of liver density using ARFI imaging did not differ significantly between the MTX-exposed and MTX-naive patients with RA. No increased rate of liver fibrosis was found among RA patients treated with MTX.
Collapse
|
38
|
Safety management in treatment with antimalarials in rheumatology. Interdisciplinary recommendations on the basis of a systematic literature review. Z Rheumatol 2021; 80:1-9. [PMID: 32236844 DOI: 10.1007/s00393-020-00785-4] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
BACKGROUND Antimalarial medication (AM) plays an important role in the treatment of rheumatic diseases. OBJECTIVE Updated evidence-based recommendations on the safety management of rheumatological treatment with AM are presented. METHODS A systematic literature search in the databases Medline (PubMed) and Cochrane identified 1160 studies on the safety of treatment with AM in rheumatology. In addition, a manual search was carried out and 67 publications considered to be particularly relevant by the authors were analyzed in more detail. These publications served as a basis for consensus-based recommendations. RESULTS Treatment with AM in rheumatology should be carried out with hydroxychloroquine (HCQ) with a dosage not exceeding 5 mg/kg body weight/day. Patients should undergo a basic ophthalmological examination within the first 6 months of AM treatment. Pre-existing maculopathy, renal insufficiency (glomerular filtration rate, GFR <60 ml/min), tamoxifen comedication, a daily dose of >5 mg/kg HCQ or treatment with chloroquine (CQ) show an increased risk for AM-induced retinopathy. These patients should undergo an annual ophthalmological check from the beginning of the treatment, whereas patients with no risk factors are recommended to start this only after 5 years of taking the medication. The ophthalmological examination should comprise at least both an appropriate subjective and an objective method and these are usually an automated visual field test and optical coherence tomography (OCT). A visual field test revealing a parafoveal sensitivity loss and an OCT showing a parafoveal circumscribed loss of the photoreceptor layer or focal interruptions of the structural line of the outer segment are signs of a possible AM retinopathy. Determination of creatine kinase (CK) and lactate dehydrogenase (LDH) in blood is appropriate to screen for cardiomyopathy and myopathy and should be checked before starting the treatment and then ca. every 3 months. The use of cardiac biomarkers, such as brain natriuretic peptide (BNP) or troponin in serum, electrocardiograph (ECG) or cardiac imaging should be considered depending on the situation. An intake of HCQ is safe during pregnancy and breastfeeding according to the current state of knowledge and is protective for mother and child in patients with systemic lupus erythematosus. CONCLUSION The updated recommendations on AM treatment in rheumatology in particular include a more rigorous measuring of doses, risk stratification in monitoring and defined ophthalmological examination methods to detect a possible retinopathy.
Collapse
|
39
|
Albrecht K, Regierer A, Strangfeld A. Risikostratifizierung für Therapieentscheidungen bei Rheumatoider Arthritis. AKTUEL RHEUMATOL 2021. [DOI: 10.1055/a-1340-0000] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
ZusammenfassungUm für die Behandlung der rheumatoiden Arthritis unter der Vielzahl an zugelassenen krankheitsmodifizierenden Antirheumatika die geeignete Therapie auszuwählen, werden Patienten anhand ihres Risikos für einen ungünstigen Krankheitsverlauf stratifiziert. Die Auswahl geeigneter Parameter zur Risikostratifizierung werden in dieser Übersichtsarbeit dargestellt. Beim heutigen Therapieziel einer Remission sind hohe Krankheitsaktivität, Funktionseinschränkungen, Begleiterkrankungen und Übergewicht relevante Faktoren für einen ungünstigen Verlauf. Weitere Einflussfaktoren auf die Therapieentscheidung wie Begleiterkrankungen, Infektionsrisiko und spezielle Risikokonstellationen wie vorausgegangene schwerwiegende Infektionen oder Malignome werden in diesem Artikel diskutiert.
Collapse
Affiliation(s)
- Katinka Albrecht
- Deutsches Rheuma-Forschungszentrum, Programmbereich Epidemiologie und Versorgungsforschung, Berlin, Deutschland
| | - Anne Regierer
- Deutsches Rheuma-Forschungszentrum, Programmbereich Epidemiologie und Versorgungsforschung, Berlin, Deutschland
| | - Anja Strangfeld
- Deutsches Rheuma-Forschungszentrum, Programmbereich Epidemiologie und Versorgungsforschung, Berlin, Deutschland
| |
Collapse
|
40
|
[Regional cooperative rheumatology centers : Networking of rheumatology in Germany for over 25 years]. Z Rheumatol 2020; 79:969-974. [PMID: 33258974 PMCID: PMC7705428 DOI: 10.1007/s00393-020-00903-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/30/2020] [Indexed: 12/25/2022]
Abstract
Over the last 25 years the regional collaborative rheumatology centers have become established throughout Germany as "catalysts" for improving rheumatological care at many different levels. With campaigns and a multitude of activities they have promoted the visibility of rheumatology in Germany together with rheumatological alliance partners and, on the scientific side, together with the German Rheumatism Research Center have contributed to the improvement of rheumatological care research in Germany. The regional cooperative rheumatology centers have become an important partner in the rheumatology network in their association as a working group of the German Society for Rheumatology and they will continue to face new tasks in the future to further improve rheumatological care in Germany.
Collapse
|
41
|
Rautenstrauch J. [Translational healthcare research : Show what is-Angela Zink, the grande dame of public health research in rheumatology]. Z Rheumatol 2020; 79:975-982. [PMID: 33258975 DOI: 10.1007/s00393-020-00904-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/30/2020] [Indexed: 11/25/2022]
Abstract
BACKGROUND As director of the program area epidemiology and health care research at the German Rheumatism Research Center, Angela Zink established the German National Database, a national register for the care of people with inflammatory rheumatic diseases and other important registers for public health research in rheumatology. OBJECTIVE This publication summarizes Angela Zink's life work and sheds light on the national significance of this extraordinary achievement from the background of the research results achieved. MATERIAL AND METHODS The available literature and personal memories of the author formed the basis of this summary. RESULTS The German National Database, which regularly collects data from more than 15,000 patients with inflammatory rheumatic diseases per year, shows that the prognosis has steadily improved in many areas, disease activity has decreased, the burden of illness due to pain or functional limitations has decreased, the incidence of incapacity for work and early retirement has decreased and those affected can nowadays participate to a much greater extent in social and working life; however, the data also revealed existing shortcomings, regional differences and differences between treatment by specialists or general practitioners. This made the database a central instrument of quality assurance. The biologics register RABBIT, in which side effects of biologics were registered and used for risk management, has also gained great importance. CONCLUSION The registers which were set up and systematically developed in the program area epidemiology under the leadership of Angela Zink, are a treasure trove of national importance. A continuation, even after the retirement of Angela Zink from active professional life, seems urgently necessary if the healthcare research of German rheumatology does not want to lose the international connection.
Collapse
Affiliation(s)
- Julia Rautenstrauch
- European League Against Rheumatism (EULAR), Seestr. 240, 8802, Kilchberg, Schweiz.
| |
Collapse
|
42
|
Fiehn C, Baraliakos X, Edelmann E, Froschauer S, Feist E, Karberg K, Ruehlmann JM, Schuch F, Welcker M, Zinke S. [Current state, goals and quality standards of outpatient care in rheumatology: position paper of the Professional Association of German Rheumatologists (BDRh)]. Z Rheumatol 2020; 79:770-779. [PMID: 32926218 DOI: 10.1007/s00393-020-00872-6] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/11/2020] [Indexed: 11/25/2022]
Abstract
Even in the era of modern guidelines, the treatment of rheumatic diseases is only as good as the framework of rheumatological care within which the treatment is carried out. The access to high-quality medical treatment for all patients is therefore essentially decisive for the prognosis of the patients. This article describes the current state of outpatient treatment in rheumatology and demonstrates which quality projects, such as treatment contracts, outpatient specialized medical treatment (ASV), digitalization and training as specialized rheumatological assistant (RFA), have been created in order to ensure the treatment of our patients. Furthermore, standards are defined that can guarantee a contemporary and guideline-conform treatment in outpatient rheumatological units. As an example it is an affirmation of the Professional Association of German Rheumatologists (BDRh) for ensuring optimal care for all rheumatology patients through early or emergency rheumatology clinics, treat to target, appropriate delegation of medical duties and diversification of treatment, thus an assurance of the quality and comprehensive treatment in rheumatology. The important topic of safeguarding the next generation of rheumatologists, which is indispensable for this, is also discussed.
Collapse
Affiliation(s)
- C Fiehn
- Rheumatologie Baden-Baden GbR, Tätigkeitsschwerpunkt Klinische Immunologie, Medical Center Baden-Baden, Beethovenstr. 2, 76530, Baden-Baden, Deutschland.
| | - X Baraliakos
- Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Bochum, Deutschland
| | - E Edelmann
- Rheumazentrum Bad Aibling-Erding, Bad Aibling, Deutschland
| | - S Froschauer
- Berufsverband Deutscher Rheumatologen e. V., Grünwald, Deutschland
| | - E Feist
- Rheumatologie, Helios Fachklinik Vogelsang-Gommern, Vogelsang-Gommern, Deutschland
| | - K Karberg
- Praxis für Rheumatologie und Innere Medizin, Berlin, Deutschland
| | - J M Ruehlmann
- Praxis für Kinderheilkunde und Kinderrheumatologie, Göttingen, Deutschland
| | - F Schuch
- Rheumatologische Schwerpunktpraxis, Erlangen, Deutschland
| | - M Welcker
- MVZ für Rheumatologie, Planegg, Deutschland
| | - S Zinke
- Rheumatologische Schwerpunktpraxis, Berlin, Deutschland
| |
Collapse
|
43
|
Fiehn C, Ness T, Weseloh C, Specker C, Hadjiski D, Detert J, Krüger K. [Safety management of the treatment with antimalarial drugs in rheumatology. Interdisciplinary recommendations based on a systematic literature search]. Z Rheumatol 2020; 79:186-194. [PMID: 32095892 DOI: 10.1007/s00393-020-00751-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
BACKGROUND Antimalarial medication (AM) plays an important role in the treatment of rheumatic diseases. OBJECTIVE Updated evidence-based recommendations on the safety management of rheumatological treatment with AM are presented. METHODS A systematic literature search in the databases Medline (PubMed) and Cochrane identified 1160 studies on the safety of treatment with AM in rheumatology. In addition, a manual search was carried out and 67 publications considered to be particularly relevant by the authors were analyzed in more detail. These publications served as a basis for consensus-based recommendations. RESULTS Treatment with AM in rheumatology should be carried out with hydroxychloroquine (HCQ) with a dosage not exceeding 5 mg/kg body weight/day. Patients should undergo a basic ophthalmological examination within the first 6 months of AM treatment. Pre-existing maculopathy, renal insufficiency (glomerular filtration rate, GFR <60 ml/min), tamoxifen comedication, a daily dose of >5 mg/kg HCQ or treatment with chloroquine (CQ) show an increased risk for AM-induced retinopathy. These patients should undergo an annual ophthalmological check from the beginning of the treatment, whereas patients with no risk factors are recommended to start this only after 5 years of taking the medication. The ophthalmological examination should comprise at least both an appropriate subjective and an objective method and these are usually an automated visual field test and optical coherence tomography (OCT). A visual field test revealing a parafoveal sensitivity loss and an OCT showing a parafoveal circumscribed loss of the photoreceptor layer or focal interruptions of the structural line of the outer segment are signs of a possible AM retinopathy. Determination of creatine kinase (CK) and lactate dehydrogenase (LDH) in blood is appropriate to screen for cardiomyopathy and myopathy and should be checked before starting the treatment and then ca. every 3 months. The use of cardiac biomarkers, such as brain natriuretic peptide (BNP) or troponin in serum, electrocardiograph (ECG) or cardiac imaging should be considered depending on the situation. An intake of HCQ is safe during pregnancy and breastfeeding according to the current state of knowledge and is protective for mother and child in patients with systemic lupus erythematosus. CONCLUSION The updated recommendations on AM treatment in rheumatology in particular include a more rigorous measuring of doses, risk stratification in monitoring and defined ophthalmological examination methods to detect a possible retinopathy.
Collapse
Affiliation(s)
- C Fiehn
- Rheumatologie Baden-Baden GbR, Tätigkeitsschwerpunkt Klinische Immunologie und Belegarzteinheit der ViDia-Kliniken Karlsruhe, Medical Center Baden-Baden, Beethovenstr. 2, 76530, Baden-Baden, Deutschland.
| | - T Ness
- Klinik für Augenheilkunde, Universitätsklinik Freiburg, Freiburg, Deutschland
| | - C Weseloh
- Deutsche Gesellschaft für Rheumatologie, Berlin, Deutschland
| | - C Specker
- Klinik für Rheumatologie und Klinische Immunologie, Kliniken Essen-Mitte, Essen, Deutschland
| | - D Hadjiski
- Rheumatologie Baden-Baden GbR, Tätigkeitsschwerpunkt Klinische Immunologie und Belegarzteinheit der ViDia-Kliniken Karlsruhe, Medical Center Baden-Baden, Beethovenstr. 2, 76530, Baden-Baden, Deutschland
| | - J Detert
- Rheumatologisch-immunologische Arztpraxis, Templin, Deutschland
| | - K Krüger
- Praxiszentrum St. Bonifatius, München, Deutschland
| |
Collapse
|
44
|
Dose tapering of biologic agents in patients with rheumatoid arthritis-results from a cohort study in Germany. Clin Rheumatol 2020; 40:887-893. [PMID: 32822057 DOI: 10.1007/s10067-020-05316-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2020] [Revised: 07/19/2020] [Accepted: 08/04/2020] [Indexed: 10/23/2022]
Abstract
OBJECTIVE To assess the association of demographic and clinical factors with the clinical decision of tapering biologic disease modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA) in daily practice. METHODS All RA patients receiving bDMARDs were documented by 14 rheumatologists when presenting in 9 specialized private practices. Statistical analyses employed multivariable logistic models for dose reduction with the covariates age, gender, disease duration until bDMARD start, smoking status, disease activity, comorbidity, functional capacity, radiographic damage, concomitant methotrexate (MTX) treatment, rheumatoid factor positivity, and glucocorticoid use. In the multivariable model (MVM), missing values were imputed. RESULTS Data of 586 RA patients on bDMARD treatment were available, 171 of which (29%) received a reduced dose. The highest rates of patients with dose reduction were seen for rituximab (67%) and infliximab (50%). The degree of dose reduction was most prominent for rituximab (57%). In the MVM, 6/11 covariates were significantly associated with dose reduction: age (odds ratio (OR) 1.03, 95% confidence interval (CI) 1.01-1.05; P = 0.002), time between disease onset and bDMARD start (OR 1.03, 95% CI 1.01-1.06; P = 0.015), DAS 28 < 2.6 (OR 1.55, 95% CI 1.01-2.37; P = 0.045), MTX therapy (OR 1.52, 95% CI 1.03-2.25; P = 0.036), comorbidity (OR 1.20, 95% CI 1.01-1.42; P = 0.036), and glucocorticoid dose (OR 0.82, 95% CI 0.76-0.89; P < 0.001). CONCLUSION DAS 28 remission, concomitant MTX, and lower glucocorticoid doses were positively associated with dose tapering of bDMARDs in RA patients. While this could be expected, the reason for the association with age, comorbidity, and the time between disease onset and bDMARD start is less clear. Key points • In rheumatology practice, tapering of biologic disease modifying antirheumatic drugs is feasible in nearly 30% of patients with rheumatoid arthritis. • The degree of dose reduction may exceed 50% of the recommended dose. • In a multivariable model, concomitant methotrexate is positively associated with dose tapering of biologic disease modifying antirheumatic drugs.
Collapse
|
45
|
[Participatory research in the German Rheumatism League. Content implementation and practical realisation of participatory research in a patient organisation]. ZEITSCHRIFT FUR EVIDENZ FORTBILDUNG UND QUALITAET IM GESUNDHEITSWESEN 2020; 155:64-70. [PMID: 32753283 DOI: 10.1016/j.zefq.2020.04.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/18/2019] [Revised: 04/21/2020] [Accepted: 04/21/2020] [Indexed: 01/05/2023]
Abstract
The German Rheumatism League ("Deutsche Rheuma-Liga") is the largest patient organisation in Germany, with about 300,000 members. In the sense of participatory research, the Deutsche Rheuma-Liga involves trained patient representatives in research projects funded by either the Deutsche Rheuma-Liga or other organisations. In order to invigorate the principle of participatory research in the field of rheumatology in Germany various measures have been undertaken: the principle of participatory research has been implemented as obligatory in the funding guidelines of the German Rheumatism League. A training course for German-speaking patients was created, and reference cards and an explanatory brochure were provided. In a letter campaign, about 70 universities and hospitals with rheumatology departments were contacted and informed about the benefits of participatory research. Since 2014, three training courses with 21 participants have been conducted. The trained patient representatives have participated in more than 30 projects up to the end of 2019. The overall experience of the patient representatives actively involved in research projects was mainly positive, and participatory research was perceived as being interesting and enriching. The implementation of participatory research in the German Rheumatism League can be described as successful. The article describes the measures taken to implement the principle of participatory research into the structures of the German Rheumatism League and summarises the experiences of patients and the patient organisation during five years of active participation in research projects.
Collapse
|
46
|
Hand- und Fußverletzungen beim Rheumatiker. Unfallchirurg 2020; 123:616-624. [DOI: 10.1007/s00113-020-00823-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
47
|
Hadjiski D, Fiehn C. Sicherheitsmanagement der Therapie mit Antimalariamitteln: was
bedeuten die neuen Empfehlungen für die Praxis? AKTUEL RHEUMATOL 2020. [DOI: 10.1055/a-1185-8566] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
ZusammenfassungAntimalariamittel (AM) haben nach wie vor eine große Bedeutung in der
Rheumatologie. Die aktualisierten Empfehlungen zum Sicherheitsmanagement mit AM
wurden auf der Basis einer systematischen Literaturaturrecherche und im
interdisziplinären Konsens erarbeitet. Verantwortlich war die Kommission
Pharmakotherapie der Deutschen Gesellschaft für Rheumatologie. Um
Nebenwirkungen frühzeitig zu entdecken, bzw. Komplikationen im
Zusammenhang mit der AM-Therapie vorzubeugen, sind folgende Maßnahmen
empfohlen: Die rheumatologische Therapie mit AM sollte mit Hydroxychloroquin
(HCQ) erfolgen und die Dosis von 5 mg/kg Körpergewicht (KG)
nicht übersteigen. In den ersten 6 Monaten der Therapie ist eine
augenärztliche Untersuchung empfohlen. Risikofaktoren für die
Entwicklung einer AM-induzierten Retinopathie sind vorbestehende Makulopathie,
Niereninsuffizienz mit glomerulärer Filtrationsrate (GFR)< 60
ml/min, Tamoxifen-Begleittherapie, Tagesdosen HCQ > 5
mg/kg KG, sowie die Therapie mit Chloroquin (CQ). Bei Vorliegen von
Risikofaktoren werden die weiteren Kontrolluntersuchungen einmal pro Jahr
empfohlen, ansonsten erst ab dem fünften Jahr, dann ebenfalls
jährlich. Die ophthalmologische Untersuchung sollte mindestens eine
subjektive und eine objektive Methode beinhalten. Empfohlen wird jeweils das
automatisierte Gesichtsfeld (aGF) und die optische Kohärenztomografie
(OCT). In der aGF lassen bei einer AM-Retinopathie eine parafoveale
Empfindlichkeitsabnahme und in der OCT eine umschriebene Verdünnung der
Photorezeptorenschicht parafoveal sowie fokale Unterbrechung der
Außensegmentstrukturlinie den Verdacht auf eine AM-Retinopathie zu. Zur
Erkennung von Kardiomyopathie bzw. Myopathie wird zu Beginn und dann alle
3–6 Monate die Bestimmung von Creatinkinase (CK) und Laktatdehydrogenase
(LDH) im Serum empfohlen. Ergänzend können bei Verdacht auf
AM-induzierte Kardiomyopathie Troponin, brain natriuretic peptide (BNP),
Elektrokardiogramm (EKG), sowie eine kardiale Magnetresonanztomografie (MRT)
erwogen werden. Bei Verdacht auf AM-induzierte Myopathie ist die Muskelbiopsie
mit elektronenmikroskopischer Untersuchung der Goldstandard. Die Behandlung mit
HCQ verursacht bei Einnahme in der Schwangerschaft keine Fehlbildungen der
ungeborenen Kinder und ist sowohl in der Schwangerschaft wie auch Stillzeit nach
gegenwärtigem Wissenstand sicher. Die aktualisierten Empfehlungen zum
Sicherheitsmanagement der Therapie mit AM enthalten strengere Dosisvorgaben,
Definition für Risikofaktoren für AM-Retinopathie und geeignete
ophthalmologische Untersuchungen, sowie Stratifizierung im Monitoring.
Collapse
Affiliation(s)
- Denitsa Hadjiski
- Tätigkeitsschwerpunkt Klinische Immunologie, Rheumatologie
Baden-Baden GbR, Baden-Baden
| | - Christoph Fiehn
- Tätigkeitsschwerpunkt Klinische Immunologie, Rheumatologie
Baden-Baden GbR, Baden-Baden
| |
Collapse
|
48
|
|
49
|
Ziegeler K, Siepmann S, Hermann S, Beck A, Lembcke A, Hamm B, Hermann KGA. Application of an advanced noise reduction algorithm for imaging of hands in rheumatic diseases: evaluation of image quality compared to standard-dose images. Rheumatol Int 2020; 40:893-899. [PMID: 32240350 DOI: 10.1007/s00296-020-04560-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2020] [Accepted: 03/17/2020] [Indexed: 10/24/2022]
Abstract
OBJECTIVES X-ray is the fundamental imaging technique in both diagnosis and follow-up of rheumatic diseases. As patients often require sequential X-rays over many years, dose reduction is of great importance. New advanced noise reduction algorithms allow for a dose reduction of up to 50%. The aim of this study was to evaluate whether quality of low-dose images is non-inferior to standard-dose images and, therefore, application of this technique is possible in the context of imaging of rheumatic diseases. METHODS A total of 298 patients with known or suspected rheumatic disease were enrolled prospectively into this study, separated into three consecutive groups: 80%, 64% and 50% tube charge reduction. All patients received imaging of one hand (laterality randomly assigned) with low-dose technique and imaging of the contralateral hand with standard-dose protocol. Images were evaluated by two independent readers who scored (on a scale of 1-5) the visualization of bony cortex, trabeculae and joint spaces of fingers and wrist separately. Additionally, soft tissue and overall contrast were evaluated on the same scale. RESULTS Overall image quality (expressed by mean sum score out of 40) of the 50% low-dose images was 31.52 (SD 1.94) vs. 31.66 (SD 1.82) for standard images (p = 0.068). Bony contours as well as trabeculae were equally well visualized in both image sets. Median scores for soft tissue visualization was slightly lower for low dose compared to standard images [4 (IQR 3.5-4) vs. 4 (IQR 3.88-4); p = 0.001]. CONCLUSIONS Overall image quality of low-dose images was not inferior to standard-dose images. Therefore, the application of low-dose technology based on advanced noise estimation algorithms in the context of imaging of rheumatic diseases is possible.
Collapse
Affiliation(s)
- Katharina Ziegeler
- Department of Radiology, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany.
| | - Stefan Siepmann
- Department of Radiology, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany
| | - Sandra Hermann
- Department of Rheumatology, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Alexander Beck
- Department of Radiology, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany
| | - Alexander Lembcke
- Department of Radiology, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany
| | - Bernd Hamm
- Department of Radiology, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany
| | - Kay Geert A Hermann
- Department of Radiology, Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany
| |
Collapse
|
50
|
|